Can supermarket pharmacies plug urgent healthcare gaps?
Pharmaceutical Technology
JUNE 18, 2024
As Asda sets up a nationwide retail pharmacy in the UK and US grocer pharmacies expand, scaling up this model will be the next frontier.
Tue.Jun 18, 2024
263 
The Blood of Exceptionally Long-Lived People Reveals Crucial Differences
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 18, 2024
(Bloomberg Creative/Getty Images) Centenarians, once considered rare, have become commonplace. Indeed, they are the fastest-growing demographic group of the world’s population, with numbers roughly doubling every ten years since the 1970s. [link] How long humans can live, and what determines a long and healthy life, have been of interest for as long as we know.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Johnson & Johnson submits BLA to FDA for lung cancer drug
Pharmaceutical Technology
JUNE 18, 2024
Johnson & Johnson has filed a BLA with the US FDA seeking approval for SC amivantamab for the treatment of non-small cell lung cancer.
Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot
Bio Pharma Dive
JUNE 18, 2024
The new vaccine, which Merck will sell as Capvaxive, will compete with Pfizer’s blockbuster Prevnar franchise.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Ability Biologics closes extended $18m seed funding round
Pharmaceutical Technology
JUNE 18, 2024
Since emerging from stealth in December 2023, the company has begun establishing its laboratories in Montreal.
ICMR-NIREH to host online training on ethical research practices
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 18, 2024
The Indian Council for Medical Research (ICMR)-National Institute for Research in Environmental Health (NIREH) will conduct an online training programme titled “Ethical Principles and Practices for Research Involving Human Participants with Environmental-Associated Ailments.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
Bio Pharma Dive
JUNE 18, 2024
Belharra will use its chemoproteomics technology to identify immune drugs for Sanofi. Elsewhere, Regenxbio mapped a regulatory path and Taysha shared updated results for its Rett treatment.
FDA approves MSD’s KEYTRUDA for advanced endometrial cancer
Pharmaceutical Technology
JUNE 18, 2024
The US FDA has granted approval for MSD’s KEYTRUDA regimen to treat primary advanced or recurrent endometrial carcinoma in adults.
Roche partners with RNA editing biotech Ascidian
Bio Pharma Dive
JUNE 18, 2024
While the Swiss pharma recently pruned its neurology drug pipeline, it has shown interest in the possibilities of RNA-focused approaches like what Ascidian is exploring.
The lasting impacts of the pandemic on cybersecurity in healthcare
Pharmaceutical Technology
JUNE 18, 2024
The high speed of the transition meant many information technology security teams had insufficient time to install adequate cybersecurity.
Lingering cholesterol can keep heart risk high. Marea Therapeutics has $190M to target it.
Bio Pharma Dive
JUNE 18, 2024
With a drug licensed from Novartis, the new biotech startup aims to reduce the ‘remnant’ cholesterol it says existing medicines can’t address.
June 18, 2024: NIH Pragmatic Trials Collaboratory to Hold Virtual Workshop July 15-16 Featuring NIH Director as Keynote
Rethinking Clinical Trials
JUNE 18, 2024
The NIH Pragmatic Trials Collaboratory will hold a virtual workshop July 15-16, 2024, on “Going From Zero to 100: Generating Evidence Through Pragmatic Research to Address Pressing Healthcare Issues.” Dr. Monica Bertagnolli, director of the NIH, will deliver the keynote presentation exploring how to identify high-priority healthcare issues that require the effort, time, and funding of a trial.
Intra-Cellular depression drug succeeds in second late-stage study
Bio Pharma Dive
JUNE 18, 2024
The results position the company to unlock what’s believed to be a multibillion-dollar sales opportunity for Caplyta, which is already used to treat schizophrenia and bipolar disorder.
Kansas AG accuses Pfizer of misrepresenting COVID vaccine, hiding safety risks in lawsuit
Fierce Pharma
JUNE 18, 2024
Kansas Attorney General is accusing Pfizer of "misrepresenting" its vaccine's safety and efficacy in a 179-page civil suit.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
UMC Utrecht and VectorY collaborate to identify biomarkers of ALS in new study
Pharma Times
JUNE 18, 2024
The progressive neurological disorder currently affects more than 200,000 people worldwide
CAR-T Cell Therapy by Shanghai Unicar-Therapy Bio-Medicine Technology for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Pharmaceutical Technology
JUNE 18, 2024
CAR-T Cell Therapy is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Diffuse Large B-Cell Lymphoma.
AstraZeneca's Truqap misses the mark in late-stage triple-negative breast cancer trial
Fierce Pharma
JUNE 18, 2024
While AstraZeneca’s Truqap bears the distinction of being the first AKT inhibitor to pass muster with the U.S. | In the late-stage CAPItello-290 study, Truqap plus the chemotherapy paclitaxel failed to help extend the lives of patients with locally advanced or metastatic triple-negative breast cancer (TNBC) over paclitaxel and placebo alone, AstraZeneca said Tuesday.
BST-2123 by Bostal Drug Delivery Co for Diabetes: Likelihood of Approval
Pharmaceutical Technology
JUNE 18, 2024
BST-2123 is under clinical development by Bostal Drug Delivery Co and currently in Phase I for Diabetes.
12 Questions with Caroline Phillips
pharmaphorum
JUNE 18, 2024
Dive into an exclusive Medscape interview with HCP Caroline Phillips as she shares her insights, experiences, and advice. Discover the key takeaways that can benefit your medical practice.
SY-104 by Syena for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Pharmaceutical Technology
JUNE 18, 2024
SY-104 is under clinical development by Syena and currently in Phase I for Multiple Myeloma (Kahler Disease).
Neuroplastogens: A novel approach to treat neurological diseases
pharmaphorum
JUNE 18, 2024
Learn about the innovative approach of using neuroplastogens, including psychedelics, to treat neurological diseases. Explore the potential benefits and risks of this novel treatment method.
SY-104 by Syena for Sarcomas: Likelihood of Approval
Pharmaceutical Technology
JUNE 18, 2024
SY-104 is under clinical development by Syena and currently in Phase I for Sarcomas.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Intra-Cellular's Caplyta scores again in major depressive disorder as blockbuster expansion comes within reach
Fierce Pharma
JUNE 18, 2024
Intra-Cellular Therapies’ surging antipsychotic Caplyta has scored again with remarkable trial results, fueling its bid for a third and potentially most lucrative indication—major depressive disord | Intra-Cellular Therapies’ surging antipsychotic Caplyta has scored again with remarkable trial results, fueling its bid for its third and potentially most lucrative indication—major depressive disorder.
CRTE-7A2 by Beijing Corregene Biotechnology for Cervical Cancer: Likelihood of Approval
Pharmaceutical Technology
JUNE 18, 2024
CRTE-7A2 is under clinical development by Beijing Corregene Biotechnology and currently in Phase I for Cervical Cancer.
CAR-T therapy achieves lupus remission breakthrough
BioPharma Reporter
JUNE 18, 2024
New data from a phase 1 clinical trial shows complete remission in 92% of lupus patients treated with a compound CAR (cCAR) T cell therapy
CRTE-7A2 by Beijing Corregene Biotechnology for Head And Neck Cancer: Likelihood of Approval
Pharmaceutical Technology
JUNE 18, 2024
CRTE-7A2 is under clinical development by Beijing Corregene Biotechnology and currently in Phase I for Head And Neck Cancer.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Novo Nordisk CEO agrees to testify on semaglutide pricing
pharmaphorum
JUNE 18, 2024
Novo Nordisk CEO agrees to appear at a Senate hearing to defend the pricing of Ozempic and Wegovy in the US.
(Atezolizumab + tiragolumab) by F. Hoffmann-La Roche for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
JUNE 18, 2024
(Atezolizumab + tiragolumab) is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Solid Tumor.
FDA says yes to MSD’s 21-valent adult pneumococcal jab
pharmaphorum
JUNE 18, 2024
The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults.The 21-valent product – formerly known as V116 – covers a wider range of Streptococcus pneumoniae serotypes than any of MSD’s earlier vaccines and eight that are not covered by any other approved pneumococcal vaccine.
Next Gen 2 by Bioprojet SCR for Narcolepsy: Likelihood of Approval
Pharmaceutical Technology
JUNE 18, 2024
Next Gen 2 is under clinical development by Bioprojet SCR and currently in Phase I for Narcolepsy.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content